KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Free Cash Flow (2019 - 2025)

GoodRx Holdings (GDRX) has disclosed Free Cash Flow for 7 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 58.95% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $97.4 million through Dec 2025, down 46.67% year-over-year, with the annual reading at $97.4 million for FY2025, 46.67% down from the prior year.
  • Free Cash Flow hit $18.3 million in Q4 2025 for GoodRx Holdings, down from $20.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $86.5 million in Q3 2024 to a low of $3.4 million in Q4 2023.
  • Historically, Free Cash Flow has averaged $30.4 million across 5 years, with a median of $26.0 million in 2021.
  • Biggest five-year swings in Free Cash Flow: crashed 79.66% in 2023 and later skyrocketed 1209.28% in 2024.
  • Year by year, Free Cash Flow stood at $23.7 million in 2021, then decreased by 29.34% to $16.7 million in 2022, then plummeted by 79.66% to $3.4 million in 2023, then surged by 1209.28% to $44.6 million in 2024, then tumbled by 58.95% to $18.3 million in 2025.
  • Business Quant data shows Free Cash Flow for GDRX at $18.3 million in Q4 2025, $20.6 million in Q3 2025, and $49.2 million in Q2 2025.